Last reviewed · How we verify
BEVA+SOC
BEVA+SOC combines bevacizumab (an anti-VEGF monoclonal antibody) with standard of care chemotherapy to inhibit tumor angiogenesis and improve chemotherapy efficacy.
BEVA+SOC combines bevacizumab (an anti-VEGF monoclonal antibody) with standard of care chemotherapy to inhibit tumor angiogenesis and improve chemotherapy efficacy. Used for Metastatic colorectal cancer (bevacizumab + standard chemotherapy), Metastatic non-small cell lung cancer (bevacizumab + standard chemotherapy).
At a glance
| Generic name | BEVA+SOC |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Anti-angiogenic monoclonal antibody + chemotherapy combination |
| Target | VEGF (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. When combined with standard chemotherapy regimens, this dual approach targets both tumor vasculature and cancer cells directly, potentially improving overall survival and progression-free survival in solid tumors.
Approved indications
- Metastatic colorectal cancer (bevacizumab + standard chemotherapy)
- Metastatic non-small cell lung cancer (bevacizumab + standard chemotherapy)
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thrombotic events
- Chemotherapy-related neutropenia
- Fatigue
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEVA+SOC CI brief — competitive landscape report
- BEVA+SOC updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI